UBS Group
OCRX

UBS Group’s Ocera Therapeutics, Inc. OCRX Stock Holding History

UBS Group’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,837
Closed -$10K – 8288
2017
Q1 		$10K Buy
+7,837
New +$9.98K ﹤0.01% 6646
2016
Q3 		– Sell
-1,040
Closed -$2K – 8180
2016
Q2 		$2K Buy
+1,040
New +$2.73K ﹤0.01% 7495

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group's OCRX Position: Q2 2017 in Review

UBS Group sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2017, closing a stake of 7,837 shares — an estimated $10K sold.

UBS Group first reported a position in OCRX in Q2 2016 and held it in 2 quarters. The position peaked at $10K in Q1 2017. 24 funds tracked by Wall St. Rank hold OCRX as of Q2 2017.

  • UBS Group reported no remaining Ocera Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • UBS Group sold 7,837 Ocera Therapeutics, Inc. shares in Q2 2017, an estimated $10K.
  • UBS Group first reported a position in Ocera Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • UBS Group's Ocera Therapeutics, Inc. position peaked at $10K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2017.

Based on UBS Group's 13F filing for Q2 2017, filed 14 Aug 2017.